title: Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia.
abstract: OBJECTIVE
  To determine the efficacy and safety of topical bevacizumab treatment in patients with ocular surface squamous neoplasia (OSSN).
  
  
  METHODS
  Six eyes of 6 patients with primary OSSN confirmed by impression cytology received topical 5 mg/mL bevacizumab 4 times daily for a period of 8 weeks. Patients were evaluated in 2-week intervals. Digital photography images were obtained at each visit and changes in the size of the lesions were analyzed by image analysis software.
  
  
  RESULTS
  The mean age of the patients was 66 ± 13 (± SD) years. Four tumors were nasal in origin and 2 tumors were temporal. The mean reduction observed in the lesion area was 43% ± 24.2% (range, 20%-71%) in the first month and 68% ± 29.7% (range, 42%-100%) in the second month when compared with the baseline area. Four patients required tumor excision at the end of the treatment period. Surgical treatment was not necessary in 2 patients due to complete disappearance of the tumor, which was confirmed by impression cytology. The visual acuity was stable in all patients and no systemic or visual side effects were observed during the study period.
  
  
  CONCLUSIONS
  Topical bevacizumab is effective as a neoadjuvant therapy combined with surgical excision for the treatment of OSSN. Topical bevacizumab may be used before surgery to decrease the size of the excision. Excision may be unnecessary in responsive patients.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Başkent University , Ankara, Turkey .
authors.forename: Leyla
authors.initials: L
authors.lastname: Asena
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Başkent University , Ankara, Turkey .
authors.forename: Dilek
authors.initials: D
authors.lastname: Dursun Altınörs
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003230:Conjunctival Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D009883:Ophthalmic Solutions; D000068258:Bevacizumab